Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis

Jun-Fang Liao; Qun Zhang; Xiao-Jing Du; Mei Lan; Shan Liu; Yun-Fei Xia; Xiu-Yu Cai; Wei Luo

doi:10.1186/s40880-019-0380-x

Table 2 Adjusted Cox multivariate analyses of prognostic factors for the matched cohort

From: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis

Endpoint	Variable	P value	HR	95% CI
OS	Gender (male vs. female)	0.334	0.62	0.24–1.63
	Age (≤ 50 vs. > 50 years)	0.175	1.63	0.80–3.30
	Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL)	0.766	1.12	0.54–2.29
	T stage (T1–2 vs. T3–4)	0.393	1.54	0.57–4.12
	N stage (N0–1 vs. N2–3)	0.022	2.26	1.12–4.53
	Clinical stage (II–III vs. IV)	0.134	1.86	0.83–4.18
	Concurrent chemotherapy (docetaxel vs. cisplatin)	0.802	0.92	0.46–1.83
DMFS	Gender (male vs. female)	0.885	0.95	0.48–1.88
	Age (≤ 50 vs. > 50 years)	0.901	0.96	0.52–1.79
	Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL)	0.039	1.85	1.030–3.31
	T stage (T1–2 vs. T3–4)	0.600	1.22	0.59–2.51
	N stage (N0–1 vs. N2–3)	0.017	2.01	1.14–3.58
	Clinical stage (II–III vs. IV)	0.530	1.27	0.61–2.64
	Concurrent chemotherapy (docetaxel vs. cisplatin)	0.827	1.07	0.60–1.88
LRFS	Gender (male vs. female)	0.146	1.85	0.81–4.21
	Age (≤ 50 vs. ≥ 50 years)	0.986	0.99	0.41–2.42
	Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL)	0.852	0.92	0.39–2.17
	T stage (T1–2 vs. T3–4)	0.418	1.58	0.52–4.79
	N stage (N0–1 vs. N2–3)	0.128	1.86	0.84–4.13
	Clinical stage (II–III vs. IV)	0.278	0.65	0.29–1.45
	Concurrent chemotherapy (docetaxel vs. cisplatin)	0.288	0.65	0.29–1.45
NRFS	Gender (male vs. female)	0.337	0.55	0.16–1.88
	Age (≤ 50 vs. > 50 years)	0.146	0.40	0.12–1.38
	Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL)	0.171	1.86	0.77–4.52
	T stage (T1–2 vs. T3–4)	0.491	0.72	0.28–1.86
	N stage (N0–1 vs. N2–3)	0.334	1.55	0.64–3.77
	Clinical stage (II–III vs. IV)	0.783	0.81	0.18–3.71
	Concurrent chemotherapy (docetaxel vs. cisplatin)	0.036	0.34	0.12–0.93

OS overall survival, EBV Epstein–Barr virus, DMFS distant metastasis-free survival, LRFS locoregional recurrence-free survival, NRFS nodal recurrence-free survival, HR hazard ratio, CI confidence interval

Back to article page